Heartseed, Inc.
TTSE:219A2,565.00
JPY
-117.00
(-4.36%)
ISIN
JP3765140003
Return %
Stock
S&P 500
1Y
38.57
14.20
3Y
- -
81.12
5Y
- -
68.34
Capital Structure
JPY
•
in mil. unless spec.Working Capital
JPY
•
in mil. unless spec.Growth Rates
JPY
•
in mil. unless spec.Quarterly Revenue
JPY
•
in mil. unless spec.Quarterly Earnings Per Share
JPY
•
in mil. unless spec.Quarterly Dividends Per Share
JPY
•
in mil. unless spec.Company Description
- CEO
- Keiichi Fukuda
- Full Time Employees
- 43
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Address
- 5th Floor, Seavans South Building Tokyo TY Japan 105-0023
- IPO Date
- Jul 30, 2024
- Website
- heartseed.jp
- Similar Companies
- Business
- Heartseed Inc. (TSE:219A) develops and commercializes regenerative medicine therapies using iPS cell-derived cardiomyocytes to treat severe heart failure with reduced ejection fraction, including dilated cardiomyopathy, old myocardial infarction, and dilated phase of hypertrophic cardiomyopathy; its lead product candidate, HS-001, comprises allogeneic iPSC-derived cardiomyocyte spheroids delivered via intramyocardial injection during open-heart surgery; HS-005 employs catheter-based administration of similar spheroids for broader clinical applicability; the company pursues additional research on autologous iPSC-derived and HLA knock-out iPSC-derived cardiomyocytes to mitigate immune rejection risks. Heartseed employs proprietary technologies for high-purity ventricular cardiomyocyte production, purification to minimize teratoma and arrhythmia risks, efficient engraftment via remuscularization, and specialized delivery devices including a recently partnered catheter system for allogeneic iPSC-derived cardiomyocyte spheroids. Founded in November 2015 and headquartered at 1-2-3 Shibaura, Minato-ku, Tokyo, Japan, the clinical-stage biotechnology company listed on the Tokyo Stock Exchange Growth Market in July 2024, terminated its June 2021 collaboration with Novo Nordisk in September 2025—under which Novo held exclusive rights outside Japan to HS-001 for up to $598 million in payments—prompting Heartseed to regain full global intellectual property control, explore new overseas partnerships, and prioritize Japanese development with existing funds following completion of a phase 1/2 trial for HS-001 in July 2025 and clearance for HS-005 phase 1/2 clinical trial notification.